{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:48:30Z","timestamp":1767494910384},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T00:00:00Z","timestamp":1321488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00432-011-1086-x","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T05:43:41Z","timestamp":1321508621000},"page":"203-212","source":"Crossref","is-referenced-by-count":8,"title":["Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity"],"prefix":"10.1007","volume":"138","author":[{"given":"Nicolai","family":"H\u00e4rtel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Klag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hanfstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin C.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Erben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,17]]},"reference":[{"key":"1086_CR1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018\u20131029","journal-title":"Lancet Oncol"},{"key":"1086_CR2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","volume":"15","author":"M Azam","year":"2008","unstructured":"Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15:1109\u20131118","journal-title":"Nat Struct Mol Biol"},{"key":"1086_CR3","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V85.12.3636.bloodjournal85123636","volume":"85","author":"R Bhatia","year":"1995","unstructured":"Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM (1995) Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 85:3636\u20133645","journal-title":"Blood"},{"key":"1086_CR4","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D et al (2005) Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development. Leukemia 19:1774\u20131782","journal-title":"Leukemia"},{"key":"1086_CR5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.leu.2402945","volume":"17","author":"F Chang","year":"2003","unstructured":"Chang F, Steelman LS, Lee JT et al (2003) Signal transduction mediated by the Ras\/Raf\/MEK\/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263\u20131293","journal-title":"Leukemia"},{"key":"1086_CR6","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","volume":"103","author":"S Chu","year":"2004","unstructured":"Chu S, Holtz M, Gupta M, Bhatia R (2004) BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103:3167\u20133174","journal-title":"Blood"},{"key":"1086_CR7","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ et al (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532\u20134539","journal-title":"Blood"},{"key":"1086_CR8","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/sj.onc.1201400","volume":"15","author":"D Cortez","year":"1997","unstructured":"Cortez D, Reuther G, Pendergast AM (1997) The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15:2333\u20132342","journal-title":"Oncogene"},{"key":"1086_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.194.3.275","volume":"3","author":"A Di Cristofano","year":"2001","unstructured":"Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, Pear WS, Van Aelst L, Pandolfi PP (2001) p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med 3:275\u2013284","journal-title":"J Exp Med"},{"key":"1086_CR10","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.leu.2402678","volume":"16","author":"JF Dorsey","year":"2002","unstructured":"Dorsey JF, Cunnick JM, Lanehart R et al (2002) Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 16:1589\u20131595","journal-title":"Leukemia"},{"key":"1086_CR11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Medic 2:561\u2013566","journal-title":"Nat Medic"},{"key":"1086_CR12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"1086_CR13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian MA, Biggs WH III, Treiber DK et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329\u2013336","journal-title":"Nat Biotechnol"},{"key":"1086_CR14","doi-asserted-by":"crossref","first-page":"20523","DOI":"10.1073\/pnas.0708800104","volume":"104","author":"O Fedorov","year":"2007","unstructured":"Fedorov O, Marsden B, Pogacic V et al (2007) A systematic interaction map of validated kinase inhibitors with Ser\/Thr kinases. Proc Natl Acad Sci USA 104:20523\u201320528","journal-title":"Proc Natl Acad Sci USA"},{"key":"1086_CR15","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","volume":"26","author":"IJ Griswold","year":"2006","unstructured":"Griswold IJ, MacPartlin M, Bumm T et al (2006) Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 26:6082\u20136093","journal-title":"Mol Cell Biol"},{"issue":"3","key":"1086_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","volume":"96","author":"B Hanfstein","year":"2011","unstructured":"Hanfstein B, Mueller MC, Kreil S et al (2011) Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 96(3):360\u2013366","journal-title":"Haematologica"},{"key":"1086_CR17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molcel.2005.06.030","volume":"19","author":"O Hantschel","year":"2005","unstructured":"Hantschel O, Wiesner S, Guttler T et al (2005) Structural basis for the cytoskeletal association of Bcr-Abl\/c-Abl. Mol Cell 19:461\u2013473","journal-title":"Mol Cell"},{"key":"1086_CR18","first-page":"585","volume":"39","author":"J Hentschel","year":"2011","unstructured":"Hentschel J, Rubio I, Eberhart M et al (2011) BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML. Int J Oncol 39:585\u2013591","journal-title":"Int J Oncol"},{"key":"1086_CR19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, La Ros\u00e9e P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18:1321\u20131331","journal-title":"Leukemia"},{"key":"1086_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian H, Jones D et al (2008) Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112:53\u201355","journal-title":"Blood"},{"key":"1086_CR21","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109:4016\u20134019","journal-title":"Blood"},{"key":"1086_CR22","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"24","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqu\u00e9 C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 24:2260\u20132270","journal-title":"N Engl J Med"},{"key":"1086_CR23","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","volume":"68","author":"H Konig","year":"2008","unstructured":"Konig H, Copland M, Chu S et al (2008a) Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 68:9624\u20139633","journal-title":"Cancer Res"},{"key":"1086_CR24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","volume":"22","author":"H Konig","year":"2008","unstructured":"Konig H, Holtz M, Modi H et al (2008b) Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22:748\u2013755","journal-title":"Leukemia"},{"key":"1086_CR25","first-page":"7149","volume":"62","author":"P La Rosee","year":"2002","unstructured":"La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ (2002a) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 62:7149\u20137153","journal-title":"Cancer Res"},{"key":"1086_CR26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.leu.2402555","volume":"16","author":"P La Rosee","year":"2002","unstructured":"La Rosee P, O\u2019Dwyer ME, Druker BJ (2002b) Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec\/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 16:1213\u20131219","journal-title":"Leukemia"},{"key":"1086_CR27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2003-04-1074","volume":"103","author":"P La Rosee","year":"2004","unstructured":"La Rosee P, Johnson K, Corbin AS et al (2004) In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 103:208\u2013215","journal-title":"Blood"},{"key":"1086_CR28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.12186","volume":"93","author":"P La Rosee","year":"2008","unstructured":"La Rosee P, Holm-Eriksen S, Konig H et al (2008) Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph\u00a0+\u00a0acute lymphoblastic leukemia patients treated with nilotinib. Haematologica 93:765\u2013769","journal-title":"Haematologica"},{"key":"1086_CR29","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"T Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U et al (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103:1659\u20131669","journal-title":"Cancer"},{"key":"1086_CR30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/leu.2008.3","volume":"22","author":"J Liu","year":"2008","unstructured":"Liu J, Joha S, Idziorek T et al (2008) BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 22:791\u2013799","journal-title":"Leukemia"},{"key":"1086_CR31","first-page":"1460","volume":"21","author":"U Matulonis","year":"1993","unstructured":"Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD (1993) Interleukin-3 and p210 BCR\/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol 21:1460\u20131466","journal-title":"Exp Hematol"},{"key":"1086_CR32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","volume":"46","author":"JA McCubrey","year":"2006","unstructured":"McCubrey JA, Steelman LS, Abrams SL et al (2006) Roles of the RAF\/MEK\/ERK and PI3\u00a0K\/PTEN\/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249\u2013279","journal-title":"Adv Enzyme Regul"},{"key":"1086_CR33","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH et al (2007) Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263\u20131284","journal-title":"Biochim Biophys Acta"},{"key":"1086_CR34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.leu.2404151","volume":"20","author":"C Miething","year":"2006","unstructured":"Miething C, Feihl S, Mugler C et al (2006) The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 20:650\u2013657","journal-title":"Leukemia"},{"key":"1086_CR35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1055\/s-2002-34939","volume":"127","author":"MC Muller","year":"2002","unstructured":"Muller MC, Lahaye T, Hochhaus A (2002) Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells. Dtsch Med Wochenschr 127:2205\u20132207","journal-title":"Dtsch Med Wochenschr"},{"key":"1086_CR36","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","volume":"92","author":"FE Nicolini","year":"2007","unstructured":"Nicolini FE, Hayette S, Corm S et al (2007) Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 92:1238\u20131241","journal-title":"Haematologica"},{"key":"1086_CR37","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/leu.2010.145","volume":"9","author":"C Nishioka","year":"2010","unstructured":"Nishioka C, Ikezoe T, Yang J, Yokoyama A (2010) Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia 9:1631\u20131640","journal-title":"Leukemia"},{"key":"1086_CR38","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619\u20131630","journal-title":"Blood"},{"key":"1086_CR39","first-page":"5995","volume":"62","author":"C Ricci","year":"2002","unstructured":"Ricci C, Scappini B, Divoky V et al (2002) Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR\/ABL-positive Cell Line. Cancer Res 62:5995\u20135998","journal-title":"Cancer Res"},{"key":"1086_CR40","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110:4055\u20134063","journal-title":"Blood"},{"key":"1086_CR41","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/0008-5472.CAN-06-1627","volume":"67","author":"A Saudemont","year":"2007","unstructured":"Saudemont A, Hamrouni A, Marchetti P et al (2007) Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res 67:4491\u20134498","journal-title":"Cancer Res"},{"key":"1086_CR42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2006.09.014","volume":"10","author":"SV Sharma","year":"2006","unstructured":"Sharma SV, Gajowniczek P, Way IP et al (2006) A common signaling cascade may underlie \u201caddiction\u201d to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10:425\u2013435","journal-title":"Cancer Cell"},{"key":"1086_CR43","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374\u20137379","journal-title":"Clin Cancer Res"},{"key":"1086_CR44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG et al (2004) JAK\/STAT, Raf\/MEK\/ERK, PI3\u00a0K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189\u2013218","journal-title":"Leukemia"},{"key":"1086_CR45","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","volume":"96","author":"JT Thiesing","year":"2000","unstructured":"Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195\u20133199","journal-title":"Blood"},{"key":"1086_CR46","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C et al (2007) Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL\u00a0+\u00a0progenitors via JAK-2\/STAT-5 pathway activation. Blood 109:2147\u20132155","journal-title":"Blood"},{"key":"1086_CR47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"1086_CR48","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1101\/gad.1588607","volume":"21","author":"RT Williams","year":"2007","unstructured":"Williams RT, den Besten W, Sherr CJ (2007) Cytokine-dependent imatinib resistance in mouse BCR-ABL\u00a0+\u00a0, Arf-null lymphoblastic leukemia. Genes Dev 21:2283\u20132287","journal-title":"Genes Dev"},{"key":"1086_CR49","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bbrc.2004.05.113","volume":"319","author":"M Yamamoto","year":"2004","unstructured":"Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O (2004) The two major imatinib resistance mutations E255\u00a0K and T315I enhance the activity of BCR\/ABL fusion kinase. Biochem Biophys Res Commun 319:1272\u20131275","journal-title":"Biochem Biophys Res Commun"},{"key":"1086_CR50","first-page":"188","volume":"62","author":"C Yu","year":"2002","unstructured":"Yu C, Krystal G, Varticovksi L et al (2002) Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells. Cancer Res 62:188\u2013199","journal-title":"Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-1086-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-011-1086-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-1086-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T16:26:43Z","timestamp":1593275203000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-011-1086-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,17]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1007\/s00432-011-1086-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,17]]}}}